Menu
Montecito
Pac Premier
Giving Guide
Loading...
You are here:  Home  >  'Amgen'  -  Page 41
Latest

FDA gives big win to Amgen in biosimilars race

By   /  Friday, September 30th, 2016  /  Central Coast Health Watch, East Ventura County, Latest news  /  Comments Off on FDA gives big win to Amgen in biosimilars race

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen paying Arrowhead for traits to develop cardiovascular drugs

By   /  Thursday, September 29th, 2016  /  Central Coast Health Watch, Latest news  /  Comments Off on Amgen paying Arrowhead for traits to develop cardiovascular drugs

Amgen will license two traits from a Pasadena pharmaceutical company to develop cardiovascular drugs under a partnership announced Sept. 29. Under the agreement, Thousand Oaks-based Amgen will pay Arrowhead Pharmaceuticals $35 million up front, $21.5 million in the form of an equity investment by Amgen in Arrowhead common stock, and up to $617 million in Read More →

Read More →
Latest

Amgen announces positive results for migraine drug

By   /  Thursday, September 29th, 2016  /  Central Coast Health Watch, Latest news  /  Comments Off on Amgen announces positive results for migraine drug

Thousand Oaks-based biotech giant Amgen announced positive data from a phase 3 study of a new migraine drug co-developed with competitor Novartis. Amgen said in a news release that, after 12 weeks, Erenumab showed a significant reduction in monthly migraine days in patients with episodic migraines treated with Erenumab compared with a placebo. In the Read More →

Read More →
Latest

FDA approves Amgen biosimilar of AbbVie’s Humira

By   /  Friday, September 23rd, 2016  /  Central Coast Health Watch, East Ventura County, Latest news  /  Comments Off on FDA approves Amgen biosimilar of AbbVie’s Humira

The Food and Drug Administration approved Amgen’s Humira biosimilar Sept. 23. Amjevita, formerly known as ABP 501 and made by Thousand Oaks-biotech giant Amgen, replicates the effects of Humira, which is approved to treat nine conditions including rheumatoid arthritis, skin disorders and colon inflammation. Humira, made by Chicago-based competitor AbbVie, typically costs $20,000 per year Read More →

Read More →
Latest

Greed drives skyrocketing cost of drugs in the U.S.

By   /  Friday, September 2nd, 2016  /  Columns, Latest news, Technology, Top Stories, Tri-County Public Companies  /  Comments Off on Greed drives skyrocketing cost of drugs in the U.S.

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Fiscal reform needed as pension time bomb ticks away

By   /  Friday, September 2nd, 2016  /  Banking & Finance, Banking Industry, Columns, Latest news, Top Stories, Tri-County Economy  /  Comments Off on Fiscal reform needed as pension time bomb ticks away

America’s summer of fiscal discontent is coming to a close on a downbeat note. The California legislature is preparing to wind up its session having stirred up a lot of controversy but done almost nothing to address the state’s ongoing pension crisis. The burgeoning shortfall now adds up to $139 billion in the CalPERS fund Read More →

Read More →
Latest

FDA approves Amgen’s Blincyto

By   /  Thursday, September 1st, 2016  /  Central Coast Health Watch, Latest news, Tri-County Public Companies  /  Comments Off on FDA approves Amgen’s Blincyto

The U.S. Food and Drug Administration approved Amgen’s drug Blincyto for treating pediatric leukemia patients Sept. 1. In Dec. 2014, the FDA approved Blincyto to treat patients with precursor B-cell acute lymphoblastic leukemia, which is a rare form of the disease. On Sept. 1, the agency extended Blincyto’s approval to include pediatric patients with another Read More →

Read More →